Cenvacibart

Monoclonal antibody

Also known as REGN7508

Phase 3underway

Evidence outlook · registrational

Venous Thromboembolism: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2027-02-20.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
Venous Thromboembolism
NCT07493304 · Regeneron Pharmaceuticals
2026-08-26 – 2031-07-18 · Venous Thromboembolism (VTE)
What this study did
NCT07697599 · Regeneron Pharmaceuticals
2026-09-07 – 2029-09-18 · Venous Thromboembolism (VTE)
What this study did
NCT07213778 · Regeneron Pharmaceuticals
2025-11-24 – 2027-07-16 · Symptomatic Venous Thromboembolism (VTE)
What this study did
NCT07015905 · Regeneron Pharmaceuticals
2025-06-25 – 2027-05-12 · Venous Thromboembolism (VTE)
What this study did
Other / comorbidity
NCT07410117 · Regeneron Pharmaceuticals
2026-03-09 – 2030-05-06 · Cancer-Associated Thrombosis (CAT)
What this study did
NCT07876492 · Regeneron Pharmaceuticals
2026-11-20 – 2029-12-15 · Secondary Stroke
What this study did
NCT07626411 · Regeneron Pharmaceuticals
2026-08-10 – 2029-12-10 · Atrial Fibrillation (AF)
What this study did
NCT07318610 · Regeneron Pharmaceuticals
2026-07-10 – 2029-11-16 · Peripheral Artery Disease (PAD)
What this study did
NCT07430956 · Regeneron Pharmaceuticals
2026-04-03 – 2029-06-26 · Atrial Fibrillation (AF)
What this study did
Phase 2 (3)
Venous Thromboembolism
NCT06299111 · Regeneron Pharmaceuticals
2024-09-20 – 2026-03-27 · Venous Thromboembolism
What this study did
NCT06454630 · Regeneron Pharmaceuticals
2024-06-27 – 2025-01-21 · Venous Thromboembolism
What this study did
Other / comorbidity
NCT07175428 · Regeneron Pharmaceuticals
2025-10-20 – 2027-04-21 · Atrial Fibrillation (AF)
What this study did
Phase 1 (4)
Other / comorbidity
NCT07876505 · Regeneron Pharmaceuticals
2026-11-23 – 2027-05-14 · Healthy Volunteers
What this study did
NCT07759167 · Regeneron Pharmaceuticals
2026-09-17 – 2027-04-02 · End-Stage Kidney Disease (ESKD)
What this study did
NCT05603195 · Regeneron Pharmaceuticals
2023-01-12 – 2024-09-17 · Healthy Volunteer
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Venous Thromboembolism: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cenvacibart: this drugPhase 3Monoclonal antibodyFactor XInot yet gradedNo reviewed efficacy summary in this indication
SHR-2004Phase 3UndisclosedFactor XInot yet gradedNo reviewed efficacy summary in this indication
Gruticibart
Phase 2(overall)
Monoclonal antibodyFactor XI
Partial signal(overall)
No reviewed efficacy summary in this indication
SRSD107Phase 2RNA / oligonucleotideFactor XInot yet gradedNo reviewed efficacy summary in this indication
Amrecibart
Phase 1(overall)
Monoclonal antibodyFactor XI
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cenvacibart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
February 2027 (2)
Phase 2Atrial Fibrillation (AF)Recruiting
Est. primary completion 2027-02-09 · NCT07175428 · CT.gov ↗
What to watch
Phase 3Venous ThromboembolismRecruiting
Est. primary completion 2027-02-20 · NCT07015905 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Healthy VolunteersNot yet recruiting
Est. primary completion 2027-03-23 · NCT07876505 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1End-Stage Kidney Disease (ESKD)Recruiting
Est. primary completion 2027-04-02 · NCT07759167 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Venous ThromboembolismRecruiting
Est. primary completion 2027-05-17 · NCT07213778 · CT.gov ↗
What to watch
2029 (5)
March 2029 (1)
Phase 3Atrial Fibrillation (AF)Recruiting
Est. primary completion 2029-03-28 · NCT07430956 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Venous ThromboembolismRecruiting
Est. primary completion 2029-06-25 · NCT07697599 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Peripheral Artery Disease (PAD)Recruiting
Est. primary completion 2029-08-18 · NCT07318610 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Atrial Fibrillation (AF)Recruiting
Est. primary completion 2029-09-11 · NCT07626411 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Secondary StrokeNot yet recruiting
Est. primary completion 2029-12-15 · NCT07876492 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 3Cancer-Associated Thrombosis (CAT)Recruiting
Est. primary completion 2030-01-23 · NCT07410117 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 3Venous ThromboembolismRecruiting
Est. primary completion 2031-07-18 · NCT07493304 · CT.gov ↗
What to watch

See the full readout calendar ↗